Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn's disease.

Crohn’s disease pyoderma gangrenosum ustekinumab

Journal

Dermatology reports
ISSN: 2036-7392
Titre abrégé: Dermatol Reports
Pays: Italy
ID NLM: 101566470

Informations de publication

Date de publication:
12 Sep 2023
Historique:
received: 14 09 2022
accepted: 03 12 2023
medline: 1 11 2023
pubmed: 1 11 2023
entrez: 1 11 2023
Statut: epublish

Résumé

Pyoderma gangrenosum (PG) is an auto-inflammatory dermatosis characterized by lesions that often cause ulcers. We present a case of successful ustekinumab treatment for acute general PG in a 31-year-old woman with coexisting Crohn's disease (CD). For a month, the patient suffered from skin ulcers, two of them deep and necrotic; a histopathological examination revealed PG. Treatment included: methylprednisolone, azathioprine, betamethasone, gentamicin and zincic ointments, antiseptic compresses, and adalimumab therapy. Due to resistance to the implemented treatment, the patient was enrolled in a clinical trial that included the administration of an anti-cytokines drug, ustekinumab. Subsequently, a significant reduction was observed in the severity of symptoms of PG with no relapse. The use of ustekinumab in patients with PG who have an inadequate response to current treatment or cannot receive first-line treatment can be considered. This applies especially to patients with accompanying autoimmune diseases such as CD.

Identifiants

pubmed: 37908604
doi: 10.4081/dr.2023.9630
pmc: PMC10614552
doi:

Types de publication

Journal Article

Langues

eng

Pagination

9630

Informations de copyright

Copyright © 2023, the Author(s).

Déclaration de conflit d'intérêts

Conflict of interest: the authors declare no potential conflict of interest. Funding: none.

Références

Aliment Pharmacol Ther. 2013 Sep;38(6):563-72
pubmed: 23914999
Arch Dermatol. 2011 Oct;147(10):1203-5
pubmed: 21680759
J Invest Dermatol. 2012 Sep;132(9):2166-70
pubmed: 22534879
MAbs. 2011 Nov-Dec;3(6):535-45
pubmed: 22123062
Clin Med (Lond). 2019 May;19(3):224-228
pubmed: 31092515
J Crohns Colitis. 2020 Jan 1;14(1):4-22
pubmed: 31711158
Gastroenterology. 2021 Jun;160(7):2496-2508
pubmed: 34051983
J Crohns Colitis. 2020 Oct 5;14(10):1488-1493
pubmed: 32318735
J Crohns Colitis. 2020 Jan 1;14(1):23-32
pubmed: 31158271
J Dermatolog Treat. 2011 Oct;22(5):254-60
pubmed: 20666672
Nat Rev Dis Primers. 2020 Oct 8;6(1):81
pubmed: 33033263
Inflamm Bowel Dis. 2018 Nov 29;24(12):2510-2517
pubmed: 29788368
J Dtsch Dermatol Ges. 2019 Jan;17(1):32-41
pubmed: 30592563
Am J Clin Dermatol. 2012 Jun 1;13(3):191-211
pubmed: 22356259
Am J Clin Dermatol. 2017 Jun;18(3):355-372
pubmed: 28224502
J Crohns Colitis. 2021 Jul 5;15(7):1236-1243
pubmed: 33367674
Digestion. 2020;101 Suppl 1:43-57
pubmed: 32172251
J Am Acad Dermatol. 2010 Apr;62(4):646-54
pubmed: 20227580
JAMA Dermatol. 2018 Apr 1;154(4):461-466
pubmed: 29450466

Auteurs

Klaudia Miklusiak (K)

Polish Red Cross Maritime Hospital with Oncology Centre, Gdynia.

Karol Miklusiak (K)

Polish Red Cross Maritime Hospital with Oncology Centre, Gdynia.

Olga Kaczmarczyk (O)

Department of Gastroenterology and Hepatology, Jagiellonian University Medical College, Cracow, Poland.

Dorota Cibor (D)

Department of Gastroenterology and Hepatology, Jagiellonian University Medical College, Cracow, Poland.

Małgorzata Zwolińska-Wcisło (M)

Department of Gastroenterology and Hepatology, Jagiellonian University Medical College, Cracow, Poland.

Classifications MeSH